<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Nkarta Inc — News on 6ix</title>
<link>https://6ix.com/company/nkarta-inc</link>
<description>Latest news and press releases for Nkarta Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 15 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/nkarta-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a24178dffbe2df109a5c.webp</url>
<title>Nkarta Inc</title>
<link>https://6ix.com/company/nkarta-inc</link>
</image>
<item>
<title>Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-announces-fda-agreement-on-outpatient-dosing-of-nkx019-in-autoimmune-disease-expanding-access-to-community-rheumatology-centers</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-announces-fda-agreement-on-outpatient-dosing-of-nkx019-in-autoimmune-disease-expanding-access-to-community-rheumatology-centers</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>Expanded treatment in community settings will reduce patient burdenOption to redose patients granted in both Ntrust-1 and Ntrust-2 studiesRheumatoid arthritis</description>
</item>
<item>
<title>Nkarta to Participate in Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-to-participate-in-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-to-participate-in-needham-virtual-healthcare-conference</guid>
<pubDate>Thu, 09 Apr 2026 11:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the 25th Annual Needham Virtual Healthcare Conference. At 11:45 a.m. ET on Wednesday, April 15, Nkarta CEO Paul Hastings will participate in a virtual panel discussion, “Cell Therapy in Autoimmune: State of the Art and What Comes Next.” Lat</description>
</item>
<item>
<title>Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-reports-fourth-quarter-and-full-year-2025-financial-results-and-corporate-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-reports-fourth-quarter-and-full-year-2025-financial-results-and-corporate-highlights</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycleInitial clinical data from</description>
</item>
<item>
<title>Nkarta to Participate in Evercore Healthcare Conference</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-participate-evercore-healthcare-conference-120900116</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-participate-evercore-healthcare-conference-120900116</guid>
<pubDate>Tue, 02 Dec 2025 12:09:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the Evercore 8th Annual Healthcare Conference on Thursday in Miami. Evercore 8th Annual Healthcare ConferenceDecember 4, 202510:50 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkar</description>
</item>
<item>
<title>Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-reports-third-quarter-2025-210100697</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-reports-third-quarter-2025-210100697</guid>
<pubDate>Mon, 10 Nov 2025 21:01:00 GMT</pubDate>
<description>Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B-cell depletion in patients receiving only cyclophosphamideEnrollment streamlined across Ntrust-1 and Ntrust-2 under a combined independent Data Safety Monitoring Board (iDSMB) to guide dose escalation Initial data for NKX019 in multiple autoimmune indications expected to be presente</description>
</item>
<item>
<title>Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights </title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-reports-third-quarter-2025-financial-results-and-corporate-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-reports-third-quarter-2025-financial-results-and-corporate-highlights</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with</description>
</item>
<item>
<title>Nkarta to Participate in November Investor Conferences</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-participate-november-investor-conferences-171400981</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-participate-november-investor-conferences-171400981</guid>
<pubDate>Thu, 30 Oct 2025 17:14:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences next month: Stifel 2025 Healthcare ConferenceNovember 12, 202510:40 a.m. ET – fireside chat TD Cowen’s Immunology & Inflammation SummitNovember 13, 20255 p.m. ET – fireside chat A simultaneous webcast of the event will be available on</description>
</item>
<item>
<title>Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-announces-poster-presentation-upcoming-140700262</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-announces-poster-presentation-upcoming-140700262</guid>
<pubDate>Wed, 22 Oct 2025 14:07:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in Chicago at the American College of Rheumatology (ACR) Convergence 2025 meeting. Nkarta will present clinical data showing that the company’s investigational therapy, NKX019, achieved robust pathogenic B-cell depletion</description>
</item>
<item>
<title>Nkarta to Participate in a September Investor Conference</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-participate-september-investor-conference-120100426</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-participate-september-investor-conference-120100426</guid>
<pubDate>Tue, 02 Sep 2025 12:01:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 9, 20258:30 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay w</description>
</item>
<item>
<title>Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-reports-second-quarter-2025-200100131</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-reports-second-quarter-2025-200100131</guid>
<pubDate>Tue, 12 Aug 2025 20:01:00 GMT</pubDate>
<description>Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter and year ended June 30</description>
</item>
<item>
<title>Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-participate-h-c-wainwright-120100223</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-participate-h-c-wainwright-120100223</guid>
<pubDate>Wed, 23 Jul 2025 12:01:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the H.C. Wainwright “HCW@Home” Series. H.C Wainwright “HCW@Home with Nkarta, Inc.”July 30, 202511:00 a.m. ET – fireside chat Register for the webcast here. A simultaneous webcast of the event will also be available on the Investors section of Nkarta’s website, www.nkart</description>
</item>
<item>
<title>Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-appoints-shawn-rose-chief-125200558</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-appoints-shawn-rose-chief-125200558</guid>
<pubDate>Fri, 06 Jun 2025 12:52:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue other opportunities in the</description>
</item>
<item>
<title>Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-reports-first-quarter-2025-200100034</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-reports-first-quarter-2025-200100034</guid>
<pubDate>Wed, 14 May 2025 20:01:00 GMT</pubDate>
<description>Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients Initial data for NKX019 in multiple autoimmune indications expected in second half of 20</description>
</item>
<item>
<title>Nkarta to Participate in an April Investor Conference</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-participate-april-investor-conference-120100207</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-participate-april-investor-conference-120100207</guid>
<pubDate>Tue, 01 Apr 2025 12:01:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 24th Annual Needham Virtual Healthcare ConferenceApril 8, 202511:00 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the we</description>
</item>
<item>
<title>Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-reports-fourth-quarter-full-200100807</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-reports-fourth-quarter-full-200100807</guid>
<pubDate>Wed, 26 Mar 2025 20:01:00 GMT</pubDate>
<description>Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune indications expected in second half of 2025Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestonesC</description>
</item>
<item>
<title>Nkarta to Participate in March Investor Conferences</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-participate-march-investor-conferences-130100164</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-participate-march-investor-conferences-130100164</guid>
<pubDate>Tue, 25 Feb 2025 13:01:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences: TD Cowen 45th Annual Health Care ConferenceMarch 3, 20253:10 p.m. ET – fireside chat Leerink Partners 2025 Global Healthcare ConferenceMarch 10, 20253:00 p.m. ET – fireside chat A simultaneous webcast of the events will be available on the Investors</description>
</item>
<item>
<title>Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-announces-ind-clearance-of-investigator-sponsored-trial-in-myasthenia-gravis-and-opening-of-enrollment-for-ntrust-2</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-announces-ind-clearance-of-investigator-sponsored-trial-in-myasthenia-gravis-and-opening-of-enrollment-for-ntrust-2</guid>
<pubDate>Thu, 05 Dec 2024 05:00:00 GMT</pubDate>
<description>Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored Trial</description>
</item>
<item>
<title>Nkarta to Participate in an Upcoming Investor Conference</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-to-participate-in-an-upcoming-investor-conference</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-to-participate-in-an-upcoming-investor-conference</guid>
<pubDate>Tue, 26 Nov 2024 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer</description>
</item>
<item>
<title>Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-reports-third-quarter-2024-financial-results-and-corporate-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-reports-third-quarter-2024-financial-results-and-corporate-highlights</guid>
<pubDate>Thu, 07 Nov 2024 05:00:00 GMT</pubDate>
<description>First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studiesEnrollment in Ntrust-2</description>
</item>
<item>
<title>Nkarta to Participate in Upcoming Investor Conference</title>
<link>https://6ix.com/company/nkarta-inc/news/nkarta-to-participate-in-upcoming-investor-conference</link>
<guid isPermaLink="true">https://6ix.com/company/nkarta-inc/news/nkarta-to-participate-in-upcoming-investor-conference</guid>
<pubDate>Tue, 03 Sep 2024 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer</description>
</item>
</channel>
</rss>